Cue Biopharma, Inc. Earnings Per Share, Basic and Diluted
Cue Biopharma, Inc. (CUE) reported Earnings Per Share, Basic and Diluted of -$0.37 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-08-04
- Cue Biopharma, Inc. earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$0.37.
- Cue Biopharma, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.44.
- Cue Biopharma, Inc. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.26.
- Cue Biopharma, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.41.
- Cue Biopharma, Inc. earnings per share, basic and diluted for fiscal 2021 was -$1.41.
- Cue Biopharma, Inc. earnings per share, basic and diluted for fiscal 2020 was -$1.56.
- Cue Biopharma, Inc. earnings per share, basic and diluted for fiscal 2019 was -$1.66.
- Cue Biopharma, Inc. earnings per share, basic and diluted for fiscal 2018 was -$1.94.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$0.37 10-Q · filed 2022-08-04 | -$0.81 10-Q · filed 2022-08-04 | -$1.08 derived: net income ÷ weighted average shares · filed 2023-08-08 | -$1.49 derived: net income ÷ weighted average shares · filed 2023-08-08 |
| 2022-03-31 | -$0.44 10-Q · filed 2022-05-10 | -$0.70 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$1.11 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$1.44 derived: net income ÷ weighted average shares · filed 2023-05-09 |
| 2021-12-31 | -$0.26 derived: net income ÷ weighted average shares · filed 2023-03-21 | -$0.67 derived: net income ÷ weighted average shares · filed 2023-03-21 | -$1.00 derived: net income ÷ weighted average shares · filed 2023-03-21 | -$1.41 10-K · filed 2022-03-16 |
| 2021-09-30 | -$0.41 10-Q · filed 2021-11-09 | -$0.74 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.16 10-Q · filed 2021-11-09 | -$1.52 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$0.33 10-Q · filed 2022-08-04 | -$0.74 10-Q · filed 2022-08-04 | -$1.11 derived: net income ÷ weighted average shares · filed 2022-08-04 | -$1.44 derived: net income ÷ weighted average shares · filed 2022-08-04 |
| 2021-03-31 | -$0.41 10-Q · filed 2022-05-10 | -$0.78 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$1.12 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$1.50 derived: net income ÷ weighted average shares · filed 2022-05-10 |
| 2020-12-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2022-03-16 | -$0.71 derived: net income ÷ weighted average shares · filed 2022-03-16 | -$1.09 derived: net income ÷ weighted average shares · filed 2022-03-16 | -$1.56 10-K · filed 2022-03-16 |
| 2020-09-30 | -$0.34 10-Q · filed 2021-11-09 | -$0.72 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$1.20 10-Q · filed 2021-11-09 | -$1.57 derived: net income ÷ weighted average shares · filed 2021-11-09 |
| 2020-06-30 | -$0.38 10-Q · filed 2021-08-09 | -$0.86 10-Q · filed 2021-08-09 | -$1.24 derived: net income ÷ weighted average shares · filed 2021-08-09 | -$1.56 derived: net income ÷ weighted average shares · filed 2021-08-09 |
| 2020-03-31 | -$0.48 10-Q · filed 2021-05-10 | -$0.86 derived: net income ÷ weighted average shares · filed 2021-05-10 | -$1.18 derived: net income ÷ weighted average shares · filed 2021-05-10 | -$1.63 derived: net income ÷ weighted average shares · filed 2021-05-10 |
| 2019-12-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$0.68 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$1.13 derived: net income ÷ weighted average shares · filed 2021-03-09 | -$1.66 10-K · filed 2021-03-09 |
| 2019-09-30 | -$0.31 10-Q · filed 2020-11-09 | -$0.76 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$1.30 10-Q · filed 2020-11-09 | -$1.87 derived: net income ÷ weighted average shares · filed 2020-11-09 |
| 2019-06-30 | -$0.46 10-Q · filed 2020-08-07 | -$1.00 10-Q · filed 2020-08-07 | -$1.57 derived: net income ÷ weighted average shares · filed 2020-08-07 | -$2.20 derived: net income ÷ weighted average shares · filed 2020-08-07 |
| 2019-03-31 | -$0.54 10-Q · filed 2020-05-07 | -$1.12 derived: net income ÷ weighted average shares · filed 2020-05-07 | -$1.74 derived: net income ÷ weighted average shares · filed 2020-05-07 | -$2.11 derived: net income ÷ weighted average shares · filed 2020-05-07 |
| 2018-12-31 | -$0.58 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$1.20 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$1.56 derived: net income ÷ weighted average shares · filed 2020-03-12 | -$1.94 10-K · filed 2020-03-12 |
| 2018-09-30 | -$0.62 10-Q · filed 2019-11-07 | -$0.99 derived: net income ÷ weighted average shares · filed 2019-11-07 | -$1.36 10-Q · filed 2019-11-07 | -$2.12 derived: net income ÷ weighted average shares · filed 2019-11-07 |
| 2018-06-30 | -$0.36 10-Q · filed 2019-08-08 | -$0.74 10-Q · filed 2019-08-08 | -$1.48 derived: net income ÷ weighted average shares · filed 2019-08-08 | -$1.96 derived: net income ÷ weighted average shares · filed 2019-08-08 |
| 2018-03-31 | -$0.37 10-Q · filed 2019-05-08 | -$1.16 derived: net income ÷ weighted average shares · filed 2019-05-08 | -$1.65 derived: net income ÷ weighted average shares · filed 2019-05-08 | -$2.09 derived: net income ÷ weighted average shares · filed 2019-05-08 |
| 2017-12-31 | -$0.95 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$1.43 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$1.85 derived: net income ÷ weighted average shares · filed 2019-03-14 | -$2.16 10-K · filed 2019-03-14 |
| 2017-09-30 | -$0.47 10-Q · filed 2018-11-13 | -$0.89 derived: net income ÷ weighted average shares · filed 2018-11-13 | -$1.20 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$0.41 10-Q · filed 2018-08-13 | -$0.73 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | -$0.31 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |